Lina Dosage/Direction for Use

Recommended dose is 5 mg orally once daily. Tablets may be taken with or without food.
Specific Populations: Body Mass Index (BMI) / Weight: No dose adjustment is necessary based on BMI/weight. BMI/weight had no clinically meaningful effect on the pharmacokinetics of linagliptin based on a population pharmacokinetic analysis.
Gender: No dose adjustment is necessary based on gender. Gender had no clinically meaningful effect on the pharmacokinetics of linagliptin based on a population pharmacokinetic analysis.
Geriatric: Age did not have a clinically meaningful impact on the pharmacokinetics of linagliptin based on a population pharmacokinetic analysis.
Pediatric: Studies characterizing the pharmacokinetics of linagliptin in pediatric patients have not yet been performed.
Race: No dose adjustment is necessary based on race. Race had no clinically meaningful effect on the pharmacokinetics of linagliptin based on available pharmacokinetic data, including subjects of White, Hispanic, Black, and Asian racial groups.
Renal Impairment: No dose adjustment recommended.
Hepatic Impairment: No dose adjustment recommended.
Pediatric Use: Safety and efficacy of linagliptin in patients under 18 years of age have not been established.